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Aim: To assess the concordance of gout management with 
the European League Against Rheumatism (EULAR) gout 
recommendations in hospital practice.
Methods: This was a retrospective review of case notes 
of patients presenting to rheumatology outpatients between 
June and December 2009 under the care of 2 consultant 
rheumatologists. Data collected consisted of demographics, 
time lag to specialist referral, comorbidities, details about 
acute and recurrent attacks, lifestyle advice and use of urate 
lowering therapies. Documented management was assessed for 
concordance with the EULAR recommendations.  
Results:  Thirty consecutive patients (27 males, 3 females) 
attending Rheumatology clinic at Mater Dei Hospital were 
recruited. Mean age at the time of survey was 59.4 ± 10.7 years, 
while mean age at diagnosis was 51.1 ± 14 years.  Documentation 
of lifestyle advice was recorded for alcohol reduction (83%), 
weight loss (43%), diet (13%), and exercise (13%). Adequate 
control of comorbidities was attained in hyperlipidaemia (71%), 
diabetes mellitus (55%) and hypertension (30%). Advice about 
smoking cessation was given to 37%. Uric acid levels below 
target were achieved in 47%.  The mean uric acid level at time 
of survey was 379 ± 146 μmol/l. This was significantly less than 
that at presentation (p=0.001). 
Conclusions: Current treatment of gout is poorly concordant 
with many of the EULAR recommendations.  Documentation 
of lifestyle modifications advice is infrequent except for alcohol 
reduction. A significant number of patents on allopurinol 
still have hyperuricaemia implying that more aggressive 
management is required to improve standard of care. A 
proforma has been developed to make and help sustain the 
necessary improvements. 
Introduction
Gout is a common inflammatory arthritis affecting about 
1-2% of the adult population.1,2  The National Health and 
Nutrition Examination Survey III (NHANES III) estimated 
the prevalence of gout at 5.1 million in US population from 
1988-1994 with 2.7 million being men aged 40 or older.3 Both 
the incidence and prevalence of gout appear to be increasing 
significantly.4 This is supported by data from New Zealand5  as 
well as from US managed care data which reported an increased 
prevalence from 2.9 cases per 1000 in 1990 to 5.2 cases per 1000 
in 1999.1 This may be accounted for by changing patterns of 
risk factors including increased longevity, dietary and lifestyle 
changes and increased prevalence of co-morbidities.2 
 Gout is characterised by chronic hyperuricaemia (defined 
as serum urate levels of >360 μmol/l), soft tissue deposition of 
monosodium urate (tophi) and acute self-limiting bouts of acute 
arthritis.6 Other forms include a chronic erosive inflammatory 
arthritis as well as uric acid kidney stones. 
Various antihyperuricaemic drugs are available including 
xanthine oxidase inhibitors, uricosurics and uricases targeting 
production, renal excretion and degradation of uric acid 
respectively.7 The availability of these new effective urate 
lowering therapies (ULT) has made it possible to attain good 
disease control in the majority of patients. Despite this, 
therapeutic targets are still not always achieved.  
The European League Against Rheumatism (EULAR) has 
issued recommendations for diagnosis8 and management of 
gout.9 These recommendations highlight the importance of 
a holistic approach for management of gout incorporating 
patient education, lifestyle modification and appropriate dose 
titration of urate-lowering medication. The aim is to achieve a 
serum uric acid level < 360 μmol/l which is the physiological 
saturation threshold of urate in the serum.6 Various studies 
have demonstrated that reduction of uric acid levels below 
360 μmol/l decreases the likelihood of both acute attacks and 
crystal load.10,11 
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Gout is largely managed in primary care. However, a 
number of patients are still referred to secondary care providers 
usually when there is a problem achieving the primary goals of 
gout management, i.e. control and prevention of the clinical 
manifestations or control of urate levels. Little is known about 
the characteristics, disease control and quality of management 
of patients attending Rheumatology outpatients.  
We carried out a case record survey about management of 
gout including lifestyle modification advice, use of ULTs and 
uric acid levels and assessed concordance with the EULAR 
recommendations for management of gout.
Methods 
This was a retrospective review of case notes of patients 
presenting to rheumatology outpatients between June 
and December 2009 under the care of two consultant 
rheumatologists. Data collected consisted of demographics, year 
and age at diagnosis, time lag to specialist referral, comorbidities, 
details about acute and recurrent attacks, lifestyle advice and use 
of ULTs. Lifestyle advice comprised alcohol intake restriction, 
weight loss and avoidance of red meat and seafood.  Biochemical 
investigations included renal function, HbA1c, lipid profile, uric 
acid levels and synovial fluid analysis.
 Patients were included in the survey if the diagnosis of 
gout was based on the presence of monosodium urate (MSU) 
crystals from joint aspiration, a history of acute arthritis of the 
1st metatarsophalangeal joint (MTPJ), a typical history (defined 
as severe pain, swelling and erythema of a joint developing 
over 6-12 hours) or the presence of tophi. Patients with 
hyperuricaemia but without any of the characteristics mentioned 
above were excluded from the study.
The EULAR 2006 recommendations for management of 
gout9 consist of 12 key evidence based recommendations focusing 
on the general, acute and chronic management of gout. They 
incorporate both pharmacological and non-pharmacological 
treatments and cover various aspects including adverse lifestyle 
modification, treatment of associated co-morbidities and risk 
factors.
A minimum standard of 60% was set for each EULAR 
recommendation given the circumstances and after discussion 
and consensus with other team members.
Results 
Thirty patients (27 males, 3 females) attending Rheumatology 
clinic at Mater Dei Hospital were recruited. Mean age at the time 
of survey was 59.4 ± 10.7 years, while mean age at diagnosis was 
51.1 ± 14 years. The mean weight was 86.2  ± 15.7 kg. The mean 
follow up time was 14 years (Table 1).
Diagnosis was made by a rheumatologist in 73% while in 
27% it was done by the General Practitioner. In 64% diagnosis 
was based on a history of arthritis involving the 1st MTPJ, while 
in 26% this was based on a typical history as explained above. 
None of the patients were initially diagnosed after finding of 
MSU crystals in the joint. The time lag from onset of symptoms 
to specialist referral was 6 months (range 2 months-20 years). 
The median serum uric acid level at time of referral was 512 
(range 231-811) μmol/l.  The median serum creatinine was 97.5 
(range 68-221) μmol/l. Four patients had a history of uric acid 
stones. None of the patients had a history of joint sepsis.
EULAR Recommendation 1 
Optimal treatment of gout requires both non-pharmacological 
and pharmacological modalities and should be tailored 
according to:
a) specific risk factors (levels of serum urate, previous 
attacks, radiographic signs)
b) clinical phase (acute/recurrent gout, intercritical gout, 
and chronic tophaceous gout)
c) general risk factors (age, sex, obesity, alcohol 
consumption, urate raising drugs, drug interactions, and 
comorbidity) 
All patients had a serum uric acid measurement at 
baseline.  The mean uric acid level at time of referral was 512 
(range 231-811) μmol/l.  Eighty-three percent were reported 
to have recurrent attacks.  The median frequency of attacks 
in the previous year was 2 (range 0-9) while median duration 
Table 1:  Characteristics of patients with gout
Age (years): mean (SD) 59.4 (10.7)
Male gender: n (%) 27 (90)
Weight (kg): mean (SD) 86.2 (15.7)
Age at diagnosis (years): mean (SD) 51.1 (14)
Serum urate at diagnosis (µmol/l): mean (range) 512 (283 - 811)
Current serum urate (µmol/l): mean (range) 379 (92 – 671)
Current serum creatinine (µmol/l): mean (range)* 97.5 (68 - 211)
Medication use: n (%)
 - on thiazide diuretics prior to first attack  8 (27)
 - on allopurinol 28 (93)
*Normal range 60 – 120 µmol/l
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of attack was 5 (range 2-12) days. Forty percent admitted to 
drinking alcohol (43% not recorded) the median amount of 
units per week was 4.5 (range1-98) while 17% denied alcohol 
intake. The type of alcohol was specified in 20% only (13% 
beer, 7% wine).  Twenty-seven percent were smokers (40% not 
recorded). The average number of cigarettes smoked was 16.5 
± 9.5 per day. 26.5% suffered from diabetes mellitus (47% not 
recorded), 67% from hypertension (30% not recorded), 43% 
had hyperlipidaemia (50% not recorded) and 23% ischemic 
heart disease (67% not recorded). Two patients were on thiazide 
diuretics at presentation. Radiographic data was not collected 
in our survey.
EULAR Recommendation 2 
Patient education and appropriate lifestyle advice regarding 
weight loss if obese, diet, and reduced alcohol (especially beer) 
are core aspects of management.
Documentation of lifestyle advice was recorded for alcohol 
reduction (83%), weight loss (43%), diet (13%), and exercise 
(13%) (Figure 1).
EULAR Recommendation 3 
Associated comorbidity and risk factors such as 
hyperlipidaemia, hypertension, hyperglycaemia, obesity, 
and smoking should be addressed as an important part of the 
management of gout. 
Adequate control of comorbidities was attained as follows: 
hyperlipidaemia (71%).   diabetes mellitus (55%), hypertension 
(30%). Advice about smoking cessation was given to 37%.
EULAR Recommendation 4
Oral colchicine and/or NSAID are first line agents for 
systemic treatment of acute attacks; in the absence of 
contraindications, an NSAID is a convenient and well 
accepted option. 
During an acute attack NSAIDS were prescribed in 50% 
while colchicine in 10%.  The type of drug used was not reported 
in the remaining cases.
Figure 1: Advice about lifestyle factor modifications Figure 2: Serum uric acid levels at first presentation 
and at last visit
EULAR Recommendation 5
High doses of colchicines lead to side effects, and low doses (for 
example, 0.5 mg three times daily) may be sufficient for some 
patients with acute gout. 
The highest dose of colchicine used did not exceed 0.5mg 
three times daily (100% concordance).
EULAR Recommendation 6
Intra-articular aspiration and injection of long acting steroid is 
an effective and safe treatment for an acute attack. 
Only 2 patients were given intra-articular steroid injections 
during an acute attack.
EULAR Recommendation 7 
Urate lowering therapy is indicated in patients with recurrent 
acute attacks, arthropathy, tophi, or radiographic changes of 
gout. 
Urate lowering therapy was started in view of recurrent 
attacks (70%), presence of gouty tophi (17%), urate stones (10%) 
and renal insufficiency (3%). ULT was initiated in line with the 
above recommendations in all patients (100% concordance). 
30% still reported two or more acute attacks despite taking 
ULT.
EULAR Recommendation 8
The therapeutic goal of urate lowering therapy is to promote 
crystal dissolution and prevent crystal formation; this is 
achieved by maintaining the serum uric acid below the 
saturation point for monosodium urate (360 μmol/l). 
The mean uric acid level at time of survey was 379 ± 146 
μmol/l. This was significantly less than that at presentation 
(p=0.001). However, only 47% achieved  uric acid levels below 
target.
EULAR Recommendation 9
Allopurinol is an appropriate long term urate lowering drug; it 
should be started at a low dose (for example, 100 mg daily) and 
increased by 100 mg every 2–4 weeks if required; the dose must 
be adjusted in patients with renal impairment; if allopurinol 
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toxicity occurs, options include other xanthine oxidase 
inhibitors, a uricosuric agent, or allopurinol desensitisation (the 
latter only in cases of mild rash). 
All patients except one were on allopurinol. The median 
dose at time of survey was 300 (range 100-600) mg/day. One 
patient experienced a hypersensitivity reaction manifested as 
widespread erythematous rash. Allopurinol desensitisation 
was carried out and the patient did not experience any further 
adverse events. 
In over 88% of patients allopurinol was started once the 
acute attack was over, the mean time being 13 weeks after the 
attack. 
EULAR Recommendation 10
Uricosuric agents such as probenecid and sulphinpyrazone can 
be used as an alternative to allopurinol in patients with normal 
renal function but are relatively contraindicated in patients 
with urolithiasis; benzbromarone can be used in patients with 
mild to moderate renal insufficiency on a named patient basis 
but carries a small risk of hepatotoxicity. 
One patient was on benzbromarone in view of renal 
impairment.
EULAR Recommendation 11
Prophylaxis against acute attacks during the first months of 
urate lowering therapy can be achieved by colchicine (0.5–1 mg 
daily) and/or an NSAID (with gastro-protection if indicated). 
Seventy-nine percent were documented to have received 
adequate cover with NSAIDs or colchicine as prophylaxis against 
an acute attack during the first month of starting ULT.
EULAR Recommendation 12
When gout associates with diuretic therapy, stop the diuretic 
if possible; for hypertension and hyperlipidaemia consider use 
of losartan and fenofibrate, respectively (both have modest 
uricosuric effects). 
Sixty-seven percent  were  documented to  have 
hypertension,10% of these were on losartan, 23% were on ACE 
inhibitors (perindopril and enalapril) 7% were on a thiazide 
diuretic,17% were on a loop diuretic and in 10% treatment was 
unrecorded. No patients were on fenofibrate. 
Discussion
Better understanding and advancements in treatment have 
made cure of gout arthropathy an achievable goal. Despite this, 
the management of chronic gout has been generally found 
to be suboptimal and poorly concordant with the EULAR 
recommendations.5  
Numerous factors may contribute to this outcome.  These 
include lack of interest in the disease due to unavailability of 
new therapeutic agents, poor compliance with ULT, and lack 
of disease awareness by patients and doctors. Patients often 
have multiple co-morbidities so gout is seen as a less important 
disease. 
 Indications about when and how to start treatment and 
achievement of uric acid thresholds have changed over the 
years and may have lead to confusion among clinicians. 
Some clinicians would start ULT after the first attack with the 
presumption that early treatment should result in easier control 
and possibly cure, while others would start therapy if attacks are 
frequent. Patients who were on Allopurinol for hyperuricaemia 
despite having never had any manifestations of gout were not 
included in our study.
Gout is mainly managed at a primary care level. However a 
number of patients are referred to secondary care. These include 
patients in whom there is a problem achieving the primary goals 
of gout management whether this is control and prevention of 
the clinical manifestations or control of serum urate levels. 
Our cohort is more likely to represent this group of patients 
who have more resistant or difficult gout. Difficult gout is often 
avoidable. However some cases of difficult gout occur because 
of limitations of current therapies. Acute attacks are very painful 
and patients are likely to seek immediate help from their general 
practitioner or self-medicate.  
Once a patient is diagnosed with gout an individualised long 
term management plan based on the patient’s characteristics 
and expectations incorporating both pharmacological and non 
pharmacological therapies is warranted.
   The aim of ULT is to achieve cure by reducing the overall 
tissue levels of uric acid, dissolve existing crystals and stopping 
new monosodium urate crystals formation. Compliance 
with ULT is known to be poor and long term adherence and 
persistence is required to achieve a good outcome. The benefit 
obtained is independent of disease severity.12 Evidence of effect 
has been demonstrated for both pharmacological13,14  and non 
pharmacological therapies.15
In the majority of patients advice about alcohol reduction 
was documented in the case notes. However, documentation 
about advice given regarding weight loss, diet and exercise 
was less consistent. Few studies have looked at the provision 
of advice about coexistent risk factors in gout. In a general 
practice study less than 30% of patients were given advice 
regarding alcohol and diet16 while recall of advice about alcohol 
reduction was only found in 40% in another study.5 There is a 
broad consensus that education about lifestyle modifications, 
adherence and efficacy improve outcomes across many chronic 
diseases, although long term benefits have not been studied. 
Alcohol is an independent risk factor for gout17 while the 
association of purine rich foods18  and weight reduction19,20  with 
gout have also been demonstrated. 
Gout has been linked with diabetes, hypertension and 
hyperlipidaemia.21 These are all important modifiable risk factors 
for cardiovascular disease together with smoking. Good quality 
care needs to address and manage all these co-morbidities. 
Hypertension and smoking were the least risk factors to be 
addressed. Choice of drugs is another important issue. Losartan 
and fenofibrate have both been shown to moderately reduce uric 
acid levels apart from their blood pressure lowering22,23  and lipid 
lowering effects respectively.24 
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The therapeutic goal of a serum urate level below 360 μmol/l 
was achieved in less than half of our cohort. Possible reasons 
could be resistant gout, inadequate attention to modifiable 
lifestyle changes, poor compliance with ULT, concern about 
hypersensitivity reactions to allopurinol and failure to increase 
the allopurinol dose as needed.  In our study compliance was 
not assessed but poor adherence to ULT has been shown in 
a number of earlier studies.25,26 Allopurinol hypersensitivity 
syndrome (AHS) is a rare but potentially life threatening disease 
characterised by an erythematous desquamating rash, fever, 
hepatitis, eosinophilia and worsening renal function. AHS may 
be barrier to use of ULT. In one of our patients, AHS was limited 
to a skin reaction and allopurinol desensitisation was effective 
(Farrugia et al; unpublished data).  Allopurinol 300mg was 
the most common prescribed dose, similar to other studies.16,27 
However, the allopurinol dose should be increased till serum uric 
acid levels fall below the target threshold given that a number 
of patients persist in having high serum uric acid levels despite 
treatment with 300mg daily.
No patients were on alternative uricosuric therapy such 
as probenecid and sulphinpyrazone while benzbromarone 
was used in one patient who had impaired renal function. 
The new selective xanthine oxidase inhibitor febuxostat or 
the recombinant urate oxidase pegloticase are currently not 
available in Malta. The awareness of the sparse local availability 
of alternatives to allopurinol could be another reason why 
patients with difficult gout are not being referred to secondary 
care by general practitioners. Another reason could be that 
patients with renal impairment are being managed directly by 
nephrologists without referral to the rheumatologists.
A major limitation in our study was the small number of 
patients recruited. The reasons for such small numbers given the 
known prevalence of gout are likely to be multifactorial. These 
include prevalent management of gout in primary care as well 
as by other specialist in hospital practice such as nephrologists, 
internists and orthopaedic surgeons. Additionally, patients 
were recruited on an ongoing basis as and when they presented 
to rheumatology clinic. Lack of a patient database of patients 
attending Rheumatology clinic may have led to ascertainment 
bias with a number of cases being missed. Finally, the 
retrospective nature and reliance on documentation may not 
necessarily give the complete picture as advice may well have 
been given although not documented. There was no mention 
whether written advice/leaflets were given which might help 
patients to remember the information given. 
For audits to be successful it is imperative to create the 
right environment where audit is an integral part of clinical risk 
management, quality control and ultimately clinical governance. 
Organisations must recognise the need for appropriate funding 
and support for this to happen. The most common barriers to 
successful audit include lack of resources, lack of expertise, 
problems between groups and inadequate protected time for 
health care team to participate.28 Setting up of a central clinical 
audit office as found in many countries would be very helpful to 
provide a structured audit programme, coordinate activity and 
improve the quality of healthcare.
Successful audits require improvements to be made and 
sustained so as to close the audit cycle. For this reason as part of 
this audit a data collection proforma has been formulated for use 
in clinical practice encompassing the EULAR recommendations 
and  made available on the Mater Dei Hospital intranet (KURA). 
Suggestions to improve the quality of care for patients with 
gout include increasing awareness and education programmes 
to doctors about the need for tighter control, and earlier 
referral of difficult gout. EULAR recommendations need to 
be disseminated to primary care physicians where most of the 
management of gout clearly takes place.  Patients should be 
provided with written information and referred to allied health 
professionals if needed for lifestyle modification advice. Future 
plans include reauditing to assess whether further improvement 
are needed and monitoring to sustain improvements.
Conclusions
Current treatment of gout is unsatisfactory and below par 
with the EULAR recommendations. Documentation of lifestyle 
modifications advice is infrequent except for alcohol reduction. 
A significant number of patents on allopurinol still have 
hyperuricaemia implying that more aggressive pharmacological 
and non-pharmacological management is required to improve 
the standard of care. 
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Bayer-Schering Pharma prize 
in obstetrics & gynaecology
The Bayer-Schering Pharma Prize in Obstetrics & 
Gynaecology for the academic year 2009-10 was awarded 
to Dr. André Zammit, who obtained the highest aggregate 
mark in the speciality during the final examinations of the 
Medicine and Surgery course. The prize was hotly contested 
by the three other student candidates who were also 
awarded a distinction grade during these examinations 
– Dr.  Lorna Attard, Dr. Christina Azzopardi, and 
Dr. Marija Farrugia. Their achievement has been rewarded 
by a small book token. Congratulations are due to all these 
candidates. In the accompanying photograph, Dr. Zammit 
is seen receiving a cheque for €250 from Professor Charles 
Savona-Ventura, Head of Obstetrics and Gynaecology at 
the Medical School with Mr. Simon Delicata, representing 
Bayer-Schering Pharma who sponsored the prize. Bayer 
Schering Pharma AG is an international healthcare company 
that is committed to sustainable development in various fields 
of healthcare including Gynaecology.
